Physician profile
Virginia E Bell
NPI 1598753329
$9,540.36
in general payments reported to CMS, 2019-2025
52 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,585 · 2022: $2,378 · 2023: $1,923 · 2024: $1,708 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794 · Consulting Fee: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.22 |
| Consulting Fee | $784.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,328.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,315.12 | 2021-2025 | |
| Biogen, INC. | $813.01 | 2023-2025 | Skyclarys |
| Astrazeneca Pharmaceuticals LP | $757.68 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $641.70 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Incyte Corporation | $410.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $337.54 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $317.81 | 2023-2025 | Gemtesa |
| Amgen INC. | $237.64 | 2021-2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $221.12 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $215.43 | 2021-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $208.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.99 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $186.26 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $180.94 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.